Best Myeloma Abstract Presentation: Long-Term Follow-Up From the MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen (BCMA) × CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Friday, October 20, 2023

1:15 PM – 1:25 PM ET

Location: Metropolitan East

Abstract Presenter(s)

María-Victoria Mateos, PhD

University Hospital of Salamanca
Zamora, Castilla y Leon, Spain